Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 601–700 of 1,044
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
Huijgen, R., Fouchier, S. W., Denoun, M., Hutten, B. A., Vissers, M. N., Lambert, G., & Kastelein, J. J. P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p023994 · Cited by 67
Grin, P. M., Dwivedi, D. J., Chathely, K. M., Trigatti, B. L., Prat, A., Seidah, N. G., Liaw, P. C., & Fox-Robichaud, A. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-28777-0 · Cited by 67
Self-citationKlug, E. Q., Llerena, S., Burgess, L. J., Fourie, N., Scott, R., Vest, J., Caldwell, K., Kallend, D., Stein, E. A., & LIBERATE-HR Investigators (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1659 · Cited by 53
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
Vafai, S. B., Täubel, J., Ashdown, T., Patel, R. S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., Gaudet, D., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601283 · Cited by 70
Lebeau, P. F., Byun, J. H., Platko, K., MacDonald, M. E., Poon, S. V., Faiyaz, M., Seidah, N. G., & Austin, R. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008094 · Cited by 67
Self-citationEffects of immunization against PCSK9 in an experimental model of breast cancer
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84734 · Cited by 67
Genetics of extreme human longevity to guide drug discovery for healthy ageing
Zhang, Z. D., Milman, S., Lin, J.-R., Wierbowski, S. D., Yu, H., Barzilai, N., Gorbunova, V. A., Ladiges, W., Niedernhofer, L. J., Suh, Y., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0247-0 · Cited by 67
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
Bhattacharya, A., Chowdhury, A., Chaudhury, K., & Shukla, P. C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188581 · Cited by 67
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
LDL-receptor mutations in Europe
Dedoussis, G. V. Z., Schmidt, H., & Genschel, J. (2004) · Human Mutation · doi:10.1002/humu.20105 · Cited by 59
DeVay, R. M., Shelton, D. L., & Liang, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.453373 · Cited by 66
Jiang, L., Xue, C., Chen, S., Dai, S., Chen, P., Sham, P. C., Wang, H., & Li, M. (2019) · Genome biology · doi:10.1186/s13059-019-1801-5 · Cited by 66
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 66
Homozygous familial hypercholesterolemia in Lebanon: A genotype/phenotype correlation
Fahed, A. C., Safa, R., Haddad, F. F., Bitar, F. F., Andary, R. R., Arabi, M. T., Azar, S. T., & Nemer, G. M. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.11.006 · Cited by 66
Citric Acid Cycle Intermediates in Cardioprotection
Czibik, G., Steeples, V., Yavari, A., & Ashrafian, H. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000220 · Cited by 66
Guella, I., Asselta, R., Ardissino, D., Merlini, P. A., Peyvandi, F., Kathiresan, S., Mannucci, P. M., Tubaro, M., & Duga, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m010009 · Cited by 58
Puri, R., Nissen, S. E., Somaratne, R. M., Cho, L., Kastelein, J. J. P., Ballantyne, C. M., Köenig, W., Anderson, T. J., Yang, J., Kassahun, H., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.019 · Cited by 66
Hess, G. P., Natarajan, P., Faridi, K. F., Fievitz, A., Valsdottir, L., & Yeh, R. W. (2017) · Circulation · doi:10.1161/circulationaha.117.028430 · Cited by 57
Inclisiran for the treatment of dyslipidemia
Nishikido, T., & Ray, K. K. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442435 · Cited by 56
Benito‐Vicente, A., Uribe, K. B., Jebari‐Benslaiman, S., Galicia-García, U., Ostolaza, H., & Martín, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061676 · Cited by 66
Targeted Strategy in Lipid-Lowering Therapy
Dayar, E., & Pecháňová, O. (2022) · Biomedicines · doi:10.3390/biomedicines10051090 · Cited by 66
Nicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65
Chemical engineering of CRISPR–Cas systems for therapeutic application
Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., & O’Reilly, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01086-0 · Cited by 65
Evolocumab (AMG 145) for primary hypercholesterolemia
Langslet, G., Emery, M. G., & Wasserman, S. M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1030395 · Cited by 65
Hori, M., Ishihara, M., Yuasa, Y., Makino, H., Yanagi, K., Tamanaha, T., Kishimoto, I., Kujiraoka, T., Hattori, H., & Harada-Shiba, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3066 · Cited by 58
Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Turpeinen, H., Ortutay, Z., & Pesu, M. (2013) · Current Genomics · doi:10.2174/1389202911314050010 · Cited by 59
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 65
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease
Zhu, X., Bian, H., & Gao, X. (2016) · Molecules · doi:10.3390/molecules21101336 · Cited by 62
PCSK9 and diabetes: is there a link?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.006 · Cited by 65
Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Vergani, L. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170518101334 · Cited by 65
Hovingh, G. K., Raal, F. J., Dent, R. E., Stefanutti, C., Descamps, O. S., Masana, L., Lira, A., Bridges, I. M., Coll, B., & SULLIVAN, D. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.003 · Cited by 65
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
Guo, Q., Feng, X., & Zhou, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.01020 · Cited by 56
Lipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martín, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 65
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64
Insights from human congenital disorders of intestinal lipid metabolism
Levy, E. H. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r052415 · Cited by 64
Levenson, A. E., Shah, A. S., Khoury, P. R., Kimball, T. R., Urbina, E. M., de Ferranti, S. D., Maahs, D. M., Dolan, L. M., Wadwa, R. P., & Biddinger, S. B. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12490 · Cited by 55
F ifty Y ears of R esearch in ARDS. Genomic Contributions and Opportunities
Reilly, J. P., Christie, J. D., & Meyer, N. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0405cp · Cited by 64
Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions
Minelli, S., Minelli, P., & Montinari, M. R. (2020) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s254016 · Cited by 64
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 64
Nordestgaard, B. G., & Tybjærg-Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 67
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Cholesterol-Lowering Agents: PCSK9 Inhibitors Today and Tomorrow
Rosenson, R. S., Hegele, R. A., & Koenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61
Guo, W., Gao, H., Li, H., Ge, S., Zhang, F., Wang, L., Shi, H., & Han, A. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c06001 · Cited by 63
Tarling, E. J., & Edwards, P. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.011 · Cited by 63
Exome Sequencing in Suspected Monogenic Dyslipidemias
Stitziel, N. O., Peloso, G. M., Abifadel, M., Cefalu, A. B., Fouchier, S., Motazacker, M. M., Tada, H., Larach, D. B., Awan, Z., Haller, J. F., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000776 · Cited by 56
Self-citationHydrogen sulfide donors: Therapeutic potential in anti-atherosclerosis
Zhang, H., Bai, Z., Zhu, L., Liang, Y., Fan, X., Li, J., Wen, H., Shi, T., Zhao, Q., & Wang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112665 · Cited by 63
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19
Apostolidis, S. A., Sarkar, A., Giannini, H. M., Goel, R. R., Mathew, D., Suzuki, A., Baxter, A. E., Greenplate, A. R., Alanio, C., Abdel-Hakeem, M. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834988 · Cited by 63
Inclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins
Warden, B. A., & Duell, P. B. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001053 · Cited by 62
Calkin, A. C., Goult, B. T., Zhang, L., Fairall, L., Hong, C., Schwabe, J. W. R., & Tontonoz, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111589108 · Cited by 62
Blom, D. J., Raal, F. J., Santos, R. D., & Marais, A. D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0809-3 · Cited by 62
Wang, X., Chen, X., Zhang, X., Su, C., Yang, M., He, W., Du, Y., Si, S., Wang, L., & Hong, B. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102650 · Cited by 54
Guo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., & Zheng, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30025 · Cited by 62
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
Konarzewski, M., Szolkiewicz, M., Sucajtys-Szulc, E., Blaszak, J., Lizakowski, S., Swierczynski, J., & Rutkowski, B. (2014) · American Journal of Nephrology · doi:10.1159/000365935 · Cited by 56
Joseph, L., & Robinson, J. G. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.04.004 · Cited by 61
Genetics of Coronary Artery Disease and Myocardial Infarction - 2013
Kessler, T., Erdmann, J., & Schunkert, H. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0368-0 · Cited by 61
Lind, S., Olsson, A. G., Eriksson, M., Rudling, M., Eggertsen, G., & Angelin, B. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01401.x · Cited by 58
Molecular pathways and agents for lowering LDL-cholesterol in addition to statins
Costet, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.006 · Cited by 61
Sorrentino, V., Fouchier, S. W., Motazacker, M. M., Nelson, J. K., Defesche, J. C., Dallinga-Thie, G. M., Kastelein, J. J. P., Kees Hovingh, G., & Zelcer, N. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs472 · Cited by 58
Ahmad, Z., Adams-Huet, B., Chen, C., & Garg, A. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.112.963587 · Cited by 55
Diogo, D., Okada, Y., & Plenge, R. M. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000012 · Cited by 61
Sun, L., Yang, X., Li, Q., Zeng, P., Liu, Y., Liu, L., Chen, Y., Yu, M., Ma, C., Li, X., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309630 · Cited by 61
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
Bayés‐Genís, A., Núñez, J. E., Zannad, F. M., Ferreira, J. P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., Lang, C. C., Ng, L. L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.057 · Cited by 61
Miname, M. H., & Santos, R. D. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.003 · Cited by 61
Humphries, S. E., Neely, R. D. G., Whittall, R. A., Troutt, J. S., Konrad, R. J., Scartezini, M., Li, K., Cooper, J. A., Acharya, J., & Neil, A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.129759 · Cited by 61
Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60
Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase
Bingham, B., Shen, R., Kotnis, S., Lo, C. F., Ozenberger, B. A., Ghosh, N., Kennedy, J. D., Jacobsen, J. S., Grenier, J. M., DiStefano, P. S., et al. (2006) · Cytometry Part A · doi:10.1002/cyto.a.20346 · Cited by 60
Lunven, C., Paehler, T., Poitiers, F., Brunet, A., Rey, J., Hanotin, C., & Sasiela, W. J. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12093 · Cited by 60
Proprotein Convertase Subtilisin/Kexin 9 Inhibitors: An Emerging Lipid-Lowering Therapy?
Dragan, S., Serban, M.-C., & Banach, M. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414539562 · Cited by 57
Natarajan, P., Pampana, A., Graham, S. E., Ruotsalainen, S. E., Perry, J. A., de Vries, P. S., Broome, J. G., Pirruccello, J. P., Honigberg, M. C., Aragam, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22339-1 · Cited by 38
Mavromatis, L. A., Rosoff, D. B., Cupertino, R. B., Garavan, H., Mackey, S., & Lohoff, F. W. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2196 · Cited by 60
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 60
Lahtinen, A. M., Havulinna, A. S., Jula, A., Salomaa, V. V., & KONTULA, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.11.015 · Cited by 60
Genetics of Diabetes Complications
Doria, A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0147-x · Cited by 60
Ohta, N., Hori, M., Takahashi, A., Ogura, M., Makino, H., Tamanaha, T., Fujiyama, H., Miyamoto, Y., & Harada‐Shiba, M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.024 · Cited by 60
Baruch, A., Mosesova, S., Davis, J. D., Budha, N. R., Vilimovskij, A., Kahn, R., Peng, K., Cowan, K. J., Harris, L. P., Gelzleichter, T. R., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.020 · Cited by 60
Pleiotropic Effects of PCSK-9 Inhibitors
Basiak, M., Kosowski, M., Cyrnek, M., Bułdak, Ł., Maligłówka, M., Machnik, G., & Okopień, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063144 · Cited by 60
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Ahamad, S., Mathew, S., Khan, W. A., & Mohanan, K. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.014 · Cited by 53
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Hori, M., Ohta, N., Takahashi, A., Masuda, H., Isoda, R., Yamamoto, S., Son, C., Ogura, M., Hosoda, K., Miyamoto, Y., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.004 · Cited by 59
The Growing Class of Novel RNAi Therapeutics
Traber, G. M., & Yu, A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000895 · Cited by 59
PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Banach, M., Rizzo, M., Obradovic, M., Montalto, G., Rysz, J., P. Mikhailidis, D., & R. Isenovic, E. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990303 · Cited by 57
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
Genetic testing for familial hypercholesterolemia—past, present, and future
Futema, M., Taylor, A., Williams, M., & Humphries, S. E. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100139 · Cited by 59
Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
Naeli, P., Mirzadeh Azad, F., Malakootian, M., Seidah, N. G., & Mowla, S. J. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00189 · Cited by 58
“PCSK9 has been recently discovered as the third gene involved in the autosomal dominant form of hypercholesterolemia (Varret et al., 1999; Abifadel et al., 2003).”
InfluentialSelf-citationTherapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Arsenault, B. J., Pelletier-Beaumont, E., Alméras, N., Tremblay, A., Poirier, P., Bergeron, J., & Després, J.-P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.010 · Cited by 58
Mayne, J., Ooi, T. C., Raymond, A., Cousins, M., Bernier, L., Dewpura, T., Sirois, F., Mbikay, M., Davignon, J., & Chrétien, M. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-70 · Cited by 58
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
Ahamad, S., & Bhat, S. A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01290 · Cited by 52
Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
Saavedra, Y. G. L., Dufour, R., & Baass, A. W. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.005 · Cited by 58
Li, G., Diogo, D., Wu, D., Spoonamore, J., Dancik, V., Franke, L., Kurreeman, F., Rossin, E. J., Duclos, G., Hartland, C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003487 · Cited by 55
Dyslipidaemia in the Middle East: Current status and a call for action
Al‐Rasadi, K., Almahmeed, W. A., AlHabib, K. F., Abifadel, M., Farhan, H. A., Alsifri, S. N., Jambart, S., Zubaid, M., Awan, Z. A., Al-Waili, K., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.925 · Cited by 58
Self-citationThe role of registries and genetic databases in familial hypercholesterolemia
Kindt, I., Mata, P., & Knowles, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000398 · Cited by 58
Diabetes alters LDL receptor and PCSK9 expression in rat liver
Niesen, M. I., Bedi, M., & Lopez, D. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.11.009 · Cited by 58
Ben Djoudi Ouadda, A., Gauthier, M.-S., Susan-Resiga, D., Girard, E., Essalmani, R., Black, M., Marcinkiewicz, J., Forget, D., Hamelin, J., Evagelidis, A., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313247 · Cited by 57
Self-citationMarais, A. D., Kim, J. B., Wasserman, S. M., & Lambert, G. C. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.004 · Cited by 57
Musunuru, K., Hickey, K. T., Al‐Khatib, S. M., Delles, C., Fornage, M., Fox, C. S., Frazier, L. Q., Gelb, B. D., Herrington, D. M., Lanfear, D. E., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/hcg.0000000000000020 · Cited by 57
The effect of insulin on circulating PCSK9 in postmenopausal obese women
Awan, Z. A., Dubuc, G., Faraj, M., Dufour, R., Seidah, N. G., Davignon, J., RABASA-LHORET, R. P. R., & Baass, A. W. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.03.022 · Cited by 57
Self-citationAn Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 57
Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression
Yang, J. H., Bang, M. A., Jang, C. H., Jo, G. H., Jung, S. K., & Ki, S. H. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.07.009 · Cited by 57
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.